16 January 2016 - The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission approval for Benepali, an etanercept biosimilar referencing Enbrel. Benepali has been granted marketing authorization in the EU for the treatment of adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis and plaque psoriasis.

For more details, go to: http://media.biogen.com/press-release/biosimilars/benepali-first-etanercept-biosimilar-referencing-enbrel-approved-european-